AA
GNMX

ALPS Advisors’s Aevi Genomic Medicine Inc GNMX Stock Holding History

ALPS Advisors’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-36,956
Closed -$163K – 647
2016
Q1 		$163K Sell
36,956
-6,334
-15% -$26.1K ﹤0.01% 608
2015
Q4 		$261K Buy
+43,290
New +$294K ﹤0.01% 659

Other funds holding GNMX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ALPS Advisors's GNMX Position: Q2 2016 in Review

ALPS Advisors sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2016, closing a stake of 36,956 shares — an estimated $163K sold.

ALPS Advisors first reported a position in GNMX in Q4 2015 and held it in 2 quarters. The position peaked at $261K in Q4 2015. 69 funds tracked by Wall St. Rank hold GNMX as of Q2 2016.

  • ALPS Advisors reported no remaining Aevi Genomic Medicine Inc position as of Q2 2016 after selling out during the quarter.
  • ALPS Advisors sold 36,956 Aevi Genomic Medicine Inc shares in Q2 2016, an estimated $163K.
  • ALPS Advisors first reported a position in Aevi Genomic Medicine Inc in Q4 2015 and held it in 2 quarters.
  • ALPS Advisors's Aevi Genomic Medicine Inc position peaked at $261K in Q4 2015.
  • 69 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2016.

Based on ALPS Advisors's 13F filing for Q2 2016, filed 27 Jul 2016.